Clinical Trial

A Study of Isoquercetin in People With Ovarian Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-23; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2026-01-27
Trial Details
NCT Number NCT07303894
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: National Institutes of Health (NIH)
Conditions Ovarian Cancer, Epithelial Ovarian Cancer, Serous Ovarian Tumor
Enrollment 90 participants
Start Date 2026-01-22
Primary Completion 2032-01 (estimated)
Study Completion 2032-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29